Zydus Lifesciences (including its subsidiaries/affiliates, hereafter referred to as 'Zydus'), a global innovation driven healthcare company announced that it has entered into an agreement with CVS Caremark® , a CVS Health® (NYSE: CVS) company to add Zituvio™, Zituvimet™ and Zituvimet™ XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) tablets to its template formulary.
CVS Caremark will add Zydus' Zituvio™ and combination products to its template formulary starting January 1, 2025.
Zituvio and combination products include Zituvio™ (sitagliptin), Zituvimet™ (sitagliptin and metformin hydrochloride) and Zituvimet™ XR (sitagliptin and metformin hydrochloride) extended-release tablets. These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route. The Zituvio range of products contain active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.